Nursery school shuts due to E. coli outbreak
A Belfast nursery school has closed for a "deep clean" following an E. coli outbreak.
The Public Health Agency (PHA) confirmed it was investigating and managing an outbreak of "Shiga toxin-producing Escherichia coli (STEC)" linked to the nursery.
The PHA did not name the school but said it had shut voluntarily for cleaning and to allow all staff and pupils to be tested for the infection.
STEC symptoms can include diarrhoea, stomach cramps and fever but most people recover within five to seven days.
However, a small proportion of patients, mainly children, can develop a serious life-threatening condition which can lead to kidney failure.
The PHA said it was "working closely with the nursery to ensure all infection control measures are in place" and was continuing to monitor the situation.
It explained "diarrhoeal illnesses can be easily spread from person to person in nursery settings due to the close contact between children and staff".
The outbreak was first reported by Belfast Live on Tuesday morning.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
2 days ago
- San Francisco Chronicle
Internet and phone outage in much of Gaza disrupts humanitarian operations and deepens isolation
CAIRO (AP) — A breakdown in communications networks in central and southern Gaza has cut many Palestinians off from the outside world for the past week, further straining aid efforts and emergency services amid continuing Israeli bombardment. Israeli strikes damaged a main connection, cutting off communications in large areas of the strip since Tuesday, according to the Telecommunications Regulatory Authority, based in the Israeli-occupied West Bank. The telecom company Paltel said Friday that internet and landline services were restored in some areas in southern Gaza, including Khan Younis, with repairs ongoing in other southern and central areas. Paltel warned in a statement to AP that ongoing attacks on the main network could make future maintenance impossible, especially due to a shortage of essential materials and resources. The Gaza Strip has experienced at least 10 communications partial and full outages since the war began in October 2023, according to Palestinian telecom company Paltel. This week's outage has impacted aid efforts, emergency services, suspended academic classes, and cut off displaced Palestinians from the rest of the territory. Palestinians in Gaza rely heavily on cell service, as unsafe roads and fuel shortages limit movement across the enclave. Humanitarians say those in affected areas will struggle to access information on aid and medical services or call for ambulances. 'Telecoms have been used as a weapon of war against civilians,' said Juliette Touma, communications director at UNRWA, the U.N. agency for Palestinian refugee that is the main service provider in Gaza. The vast majority of UNRWA workers don't have connectivity in the areas affected by the outages. As a result, they and other aid workers have struggled to deliver aid and coordinate with one another, Touma told the AP. 'Sometimes we get a signal when a team member has the courage to go on the rooftop of a building, which is extremely dangerous under strikes, and they send us a message that they're alive. I can't tell you how much of a relief it is, but they're more sporadic and less regular,' said Touma. Some people rely on E-sims, but they are not compatible with all devices and can only work in certain areas. Unreliable mobile service Over 70% of telecommunications networks in Gaza has been partially or completely destroyed as of August 2024 since the war began, according to statistics released by the Palestinian Ministry of Telecommunication and Digital Economy, cited by the Palestine Economic Policy Research Institute. However, Paltel said technical teams offered some technical solutions that would restore services. When they hear nearby strikes, Palestinians without connection don't know whether evacuation orders are issued and where should they relocate to, said Shaina Low, the Norwegian Refugee Council's communications adviser. 'This also means that people are isolated. They can't communicate with their family and friends inside of Gaza and understand what the current situation is or get external support from networks outside,' she said. Limited or unreliable mobile service has made it difficult for ambulances and civil defense teams to reach people in need of life-saving assistance, Low added. Fikr Shalltoot, Gaza director for the group Medical Aid for Palestinians, said its doctors working in hospitals and clinics in effected areas can't document or share their work with managers. 'Targeted daily' Meanwhile, with Gaza's university campuses heavily damaged, the internet has become the only way to continue education. But outages have forced educators to cancel classes and exams. 'It is, unfortunately, like a never-ending vicious cycle of suffering because when this issue is resolved in the north, the problem appears in the south,' said Mohammed Shbair, vice president for administrative and financial affairs, at al-Azhar University in Gaza. 'Students cannot reach universities because they are destroyed, and they can't even reach areas where the internet is available in cafes or displacement tents, as they are now being targeted daily and systematically by Israeli strikes,' said Shbair, an associate professor of public law. Online banking, a key alternative amid cash shortages, has also become unavailable. Palestinians who rely on online transfers to pay suppliers can no longer do so under the current conditions, according to Low. The outage complicates humanitarian operations and adds to the 'toxic stress' families face daily, said UNICEF spokesperson Tess Ingram. 'In a context of incessant bombardments, mass casualty events linked to food distributions, rising malnutrition and dwindling access to clean water, connectivity is a real lifeline for families in Gaza,' she said.
Yahoo
2 days ago
- Yahoo
Liver-Assessment Tool Hepatoscope® Steadily Expands Installed-Base Validating Its Clinical and Commercial Viability
E-Scopics' Ultraportable, Software-Based Hepatoscope In Use Across Leading Institutions and Clinics AIX-EN-PROVENCE, France, June 20, 2025--(BUSINESS WIRE)--After successfully exhibiting its unique software-based liver assessment tool Hepatascope at the DDW Convention in San Diego and the EASL Conference in Amsterdam, the France-based medical ultrasound company E-Scopics will demonstrate the technology at the June 2025 American Diabetes Association Conference in Chicago. The technology is seeing expanded adoption, with the company reporting that it has established the technology in a number of important sites in the US and Europe, validating its clinical and commercial viability. In the span of a few short years, the company has successfully adapted its premium ultrafast imaging point-of-care systems into GI and primary care, putting the system into the hands of a growing number of users who recognize its clinical value and importance in improving the standard of care for patients. In the process, E-Scopics has completely disrupted the field of portable ultrasound by leveraging proprietary technology using software-based image reconstruction. In 2023 E-Scopics began to commercialize its first product, Hepatoscope, both in the USA and in EMEA countries. The company's mid-term goal is to increase its footprint globally, starting its expansion to most European countries, where patients at risk of chronic liver diseases are. Hepatoscope continues to gain recognition as an alternative to legacy technology, from major institutions and all-size healthcare institutions across the USA. E-Scopics Founder and CEO Claude Cohen-Bacrie, who brings deep experience developing and taking to market cutting-edge ultrasound technologies, commented, "Our ambition is to bring premium quantitative ultrasound modalities and tools at the point-of-care, in the hands of non-ultrasound expert users, for the benefit of healthcare systems and patients. Making patients' journey and care pathways simpler and more efficient is our priority. We are so pleased that our backers- both leading users who understand the clinical and business partners who get the commercial potential, are in it for the long haul- and really excited about it." The company recognized MASLD was on the rise globally, and the need to bring the healthcare community a less expensive, more portable, and easier-to-use tool to accurately screen for the disease. It was very deliberate, developing a tool that was simple to use and reducing costs. The Hepatoscope application can easily be loaded onto a consumer laptop or tablet and rapidly deployed in the field. In addition to ease-of-use, the company saw Ultrasound-as-a-Service model as means to open access to any clinic via an affordable monthly or pay-per-use subscription, innovating on the business side. Cohen-Bacrie continued, "We see a healthier patient population coming out of a world where there is healthy business competition which drives innovation. We would not be talking about elastography outside of this important competitive environment. Especially where liver assessment is concerned, patients really need it, clinicians are asking for better and more affordable tools, and the FDA and payers endorse it." The numbers bear the need out. Approximately 1.5 million patients have been diagnosed with metabolic dysfunction associated steatohepatitis (MASH) in the U.S., and it is estimated that the precursor to MASH—metabolic dysfunction-associated steatotic liver disease or MASLD—will affect more than half of all American adults by 2040. The MASLD spectrum ranges from a simple, generally nonprogressive fat buildup in the liver all the way to MASH, which can lead to cirrhosis, hepatocellular carcinoma, and death. The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually. Therefore, it is crucial to identify these patients and take care of them as early as possible. "As consumers we've become conditioned to expect the latest and greatest personal computing and communications tools, they simply make us more efficient in day-to-day tasks, said Dr. Julio Gutierrez, Associate Professor of Medicine at Scripps Center for Organ Transplant in La Jolla, CA and an early adopter of Hepatoscope. "I think of E-Scopics like Apple and have come to expect continuous innovation, and the clinical impact has been significant." Dr. Cyrielle Caussy MD, PhD, Professor of Nutrition and an Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital in France, asserted, "In the endocrine and diabetology practice, approximately 80% of patients screened show low liver stiffness, which means they can be reassured without further referral or testing. By reducing the time between initial screening and specialty care, the Hepatoscope improves both the efficiency and quality of patient management. For high-risk patients, we can initiate care pathways much earlier, potentially slowing or halting the progression of liver disease. At the same time, for low-risk individuals, we avoid unnecessary referrals, which frees up resources and improves overall healthcare system efficiency. Importantly, patients appreciate the immediate feedback they receive, which encourages compliance with treatment plans and lifestyle modifications." E-Scopics will demonstrate Hepatoscope at the American Diabetes Association annual conference in Chicago in Booth #3527. Visitors may walk in and also book a time by emailing About E-Scopics: E-Scopics S.A.S is a MedTech company headquartered in France. The company advances the accessibility, affordability, and ease of use of premium ultrasound tools at the point of care. Its agile software platform has dematerialized and automated ultrasound imaging technologies. Ultrasound-as-a-Service products derived from this platform are specific Apps commercialized with pay-per-use or subscription business models. The company's first product, the Hepatoscope, leverages quantitative imaging capabilities to help any clinician assess liver fibrosis and steatosis—important markers of MASLD-MASH—non-invasively at the bedside. To learn more, visit View source version on Contacts Dan ConleyBeacon Communicationsdconley@ 312-593-8461 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business Wire
Liver-Assessment Tool Hepatoscope® Steadily Expands Installed-Base Validating Its Clinical and Commercial Viability
AIX-EN-PROVENCE, France--(BUSINESS WIRE)--After successfully exhibiting its unique software-based liver assessment tool Hepatascope at the DDW Convention in San Diego and the EASL Conference in Amsterdam, the France-based medical ultrasound company E-Scopics will demonstrate the technology at the June 2025 American Diabetes Association Conference in Chicago. The technology is seeing expanded adoption, with the company reporting that it has established the technology in a number of important sites in the US and Europe, validating its clinical and commercial viability. In the span of a few short years, the company has successfully adapted its premium ultrafast imaging point-of-care systems into GI and primary care, putting the system into the hands of a growing number of users who recognize its clinical value and importance in improving the standard of care for patients. In the process, E-Scopics has completely disrupted the field of portable ultrasound by leveraging proprietary technology using software-based image reconstruction. In 2023 E-Scopics began to commercialize its first product, Hepatoscope, both in the USA and in EMEA countries. The company's mid-term goal is to increase its footprint globally, starting its expansion to most European countries, where patients at risk of chronic liver diseases are. Hepatoscope continues to gain recognition as an alternative to legacy technology, from major institutions and all-size healthcare institutions across the USA. E-Scopics Founder and CEO Claude Cohen-Bacrie, who brings deep experience developing and taking to market cutting-edge ultrasound technologies, commented, 'Our ambition is to bring premium quantitative ultrasound modalities and tools at the point-of-care, in the hands of non-ultrasound expert users, for the benefit of healthcare systems and patients. Making patients' journey and care pathways simpler and more efficient is our priority. We are so pleased that our backers- both leading users who understand the clinical and business partners who get the commercial potential, are in it for the long haul- and really excited about it.' The company recognized MASLD was on the rise globally, and the need to bring the healthcare community a less expensive, more portable, and easier-to-use tool to accurately screen for the disease. It was very deliberate, developing a tool that was simple to use and reducing costs. The Hepatoscope application can easily be loaded onto a consumer laptop or tablet and rapidly deployed in the field. In addition to ease-of-use, the company saw Ultrasound-as-a-Service model as means to open access to any clinic via an affordable monthly or pay-per-use subscription, innovating on the business side. Cohen-Bacrie continued, 'We see a healthier patient population coming out of a world where there is healthy business competition which drives innovation. We would not be talking about elastography outside of this important competitive environment. Especially where liver assessment is concerned, patients really need it, clinicians are asking for better and more affordable tools, and the FDA and payers endorse it.' The numbers bear the need out. Approximately 1.5 million patients have been diagnosed with metabolic dysfunction associated steatohepatitis (MASH) in the U.S., and it is estimated that the precursor to MASH—metabolic dysfunction-associated steatotic liver disease or MASLD—will affect more than half of all American adults by 2040. The MASLD spectrum ranges from a simple, generally nonprogressive fat buildup in the liver all the way to MASH, which can lead to cirrhosis, hepatocellular carcinoma, and death. The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually. Therefore, it is crucial to identify these patients and take care of them as early as possible. 'As consumers we've become conditioned to expect the latest and greatest personal computing and communications tools, they simply make us more efficient in day-to-day tasks, said Dr. Julio Gutierrez, Associate Professor of Medicine at Scripps Center for Organ Transplant in La Jolla, CA and an early adopter of Hepatoscope. 'I think of E-Scopics like Apple and have come to expect continuous innovation, and the clinical impact has been significant.' Dr. Cyrielle Caussy MD, PhD, Professor of Nutrition and an Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital in France, asserted, 'In the endocrine and diabetology practice, approximately 80% of patients screened show low liver stiffness, which means they can be reassured without further referral or testing. By reducing the time between initial screening and specialty care, the Hepatoscope improves both the efficiency and quality of patient management. For high-risk patients, we can initiate care pathways much earlier, potentially slowing or halting the progression of liver disease. At the same time, for low-risk individuals, we avoid unnecessary referrals, which frees up resources and improves overall healthcare system efficiency. Importantly, patients appreciate the immediate feedback they receive, which encourages compliance with treatment plans and lifestyle modifications.' E-Scopics will demonstrate Hepatoscope at the American Diabetes Association annual conference in Chicago in Booth #3527. Visitors may walk in and also book a time by emailing About E-Scopics: E-Scopics S.A.S is a MedTech company headquartered in France. The company advances the accessibility, affordability, and ease of use of premium ultrasound tools at the point of care. Its agile software platform has dematerialized and automated ultrasound imaging technologies. Ultrasound-as-a-Service products derived from this platform are specific Apps commercialized with pay-per-use or subscription business models. The company's first product, the Hepatoscope, leverages quantitative imaging capabilities to help any clinician assess liver fibrosis and steatosis—important markers of MASLD-MASH—non-invasively at the bedside. To learn more, visit
